PXS

Pharmaxis (PXS)

Stock Code

PXS

Stock Exchange

ax

Pharmaxis (PXS) is a pharmaceutical company specialising in the research, development and commercialisation of therapeutic pharmaceutical products. The Company manufactures specialty products for use in the diagnosis and treatment of chronic respiratory and immune disorders. Pharmaxis was listed on the Australian Stock Exchange on 10th November, 2003. Pharmaxis is based in Sydney, with offices also in the US, UK and China. It listed on the on NASDAQ (symbol PXSL) in August 2005.

Pharmaxis $20.8m loss 1H


Phamaceutical drug maker, Pharmaxis (ASX:PXS) have released its first half results for FY2013 to stockmarket traders and investors.

  • Pharmaxis reported a $20.8 million loss for the first half to December, an increase of 6 percent in losses.

Sharemarket Events on Monday


There would be no floats in the sharemarket list of events on Monday, November 21,
2011, but there will be five upcoming ex-
dividends and a couple of Annual General Meetings scheduled on the
same day.

Ex-Dividends

Pharmaxis' Cystic Fibrosis Drug Bronchitol Approved in Europe


Pharmaxis (ASX:PXS), an Australian biotech listed company has been approved in Europe to distribute Bronchitol, which treats cystic fibrosis in adults and is the first new drug in 15 years to treat the condition. Pharmaxis will be able to supply their drug to Europe's 27 countries.

Pharmaxis Profits after Disappointment


Pharmaxis (ASX:PXS) is dialing back on losses suffered last week after a European committee strongly indicated it was going to reject the company’s cystic fibrosis drug Bronchitol. Shares yesterday rose 25 cents, or 27.2 percent, to $1.17, in addition to Friday’s 29.6 percent increase.

Although the health index fell 0.8 percent, the drug manufacturer was one of yesterday’s stellar performers, according to E L & C Baillieu Stockbroking director Richard Morrow.

Pharmaxis Shares Dive After Drug Rejection


After chief executive Alan Robertson sold 500,000 shares in the company, Pharmaxis (ASX:PXS) stock dropped 74 percent to 86 cents per share today. The fall in shares came after a European panel vetoed the release of the company's cystic fibrosis drug Bronchitol.

Pharmaxis Dividends

1 September, 2010 - 13:29

Study the dividend history for PHARMAXIS LTD. A taxable payment declared by a company's board of directors and given to its shareholders out of the company's current or retained earnings, usually quarterly. Dividends are usually given as cash (cash dividend), but they can also take the form of stock (stock dividend) or other property. Dividends provide an incentive to own stock in stable companies even if they are not experiencing much growth. Companies are not required to pay dividends.

Syndicate content

Recommended Websites